In lung cancer patients brain metastases develop with a high frequency. For years
radiotherapy has been the standard treatment for these patients. Here we review the …

Simple Summary In order to clarify whether an early development of brain metastases from
non-small cell lung cancer represents a poor prognostic factor for further survival we …

Abstract Between 30% and 50% of patients with non–small-cell lung cancer (NSCLC) will
develop cerebral metastases in the course of their illness. As improvements are made in the …

Purpose/Objective (s) Immune checkpoint inhibitors (ICI) and epidermal growth factor
receptor-tyrosine kinase inhibitors (EGFR-TKI) have shown responses in the management of …

Background: Brain metastases develop frequently in patients with non-small cell lung cancer
(NSCLC), and the prognosis for these patients is very poor. We evaluated the role of …

Lung cancer is the leading cause of cancer-related death in the United States.
Approximately 20% of these patients present with brain metastases (BMs). Surgical …

In early 2020, the US Food and Drug Administration (FDA) approved tucatinib, an oral
tyrosine kinase inhibitor (TKI) of the protein ERBB2 (formerly HER2), in combination with …

The therapeutic landscape in patients with advanced non-small-cell lung cancer harboring
oncogenic biomarkers has radically changed with the development of targeted therapies …

Brain metastases (BM) occur frequently in many cancers, particularly non–small cell lung
cancer (NSCLC), breast cancer, and melanoma. The development of BM is associated with …

Opinion statement Management of non-small cell lung cancer (NSCLC) with brain
metastasis (BrM) has been revolutionized by identification of molecular subsets that have …